Latest App Notes & Case Studies

Discover an automated processing workflow that utilizes both EAD and CID data for the most confident characterization of pharmaceutical drug metabolites.

Metabolism is a key driver of CAR-T cell fitness and function. Hence, metabolic preconditioning methods can enhance the bioenergetic capacity of CAR-T cells in culture, supporting their persistence and antitumor activity

The ability to study transcript isoforms in detail could have a significant impact on our understanding of health and disease. However, most commonly, bulk sequencing is the selected method that only provides an average of the transcripts expressed across your sample of cells.

Protein-targeting chimeras (PROTACs) have gained significant attention recently due to their high potency in nanomolar drug concentrations and target selectivity. However, low test concentrations in complex matrices present analytical challenges.

Understanding the effects of in vitro drug metabolism is a key aspect of drug discovery and development. However, researchers must be able to make confident decisions quickly and easily.

Glucuronidation is an essential metabolic pathway for drug clearance and its characterization is crucial for optimizing the efficiency and safety of drug candidates.

Early ADME studies are used to determine if a drug candidate is prone to metabolic breakdown or oxidation/conjugation. Glucuronide conjugation is difficult to characterize using MS/MS alone, therefore fragmentation is also required to obtain structural information.

Developed for performance in human serum and plasma, the SomaScan Assay v4.1 can measure approximately 7,000 unique human protein analytes in small volumes of biological samples.

Download this app note to learn how you can select 20 individual CTCs in 10 minutes, this approach can be used for DNA, RNA or proteome analysis as well as how these target cells are selected and isolated in high purity from heterogenous backgrounds.

Metabolism has emerged as a key driver of T-cell antitumor function. This means that modulating metabolic programs of T cells can be used as a strategy to improve the antitumor efficacy of adoptive T-cell therapies.